In a Time of Universal Deceit, Telling the Truth is Revolutionary.
Monday, March 27, 2023
Menu
F.D.A. Revises Its Letter for Nonapproval of Drugs
Drug makers whose products are not ready for approval in the U.S. will soon get the word from regulators in a new format intended partly to avoid scaring investors.
Drug makers whose products are not ready for approval in the U.S. will soon get the word from regulators in a new format intended partly to avoid scaring investors.
